Bushen Huoxue Recipe inhibits endometrial epithelial-mesenchymal transition through the transforming growth factor-β/nuclear factor kappa-B pathway to improve polycystic ovary syndrome-mediated infertility

References

• Yildiz BO, Bozdag G, Yapici Z, et al. Prevalence, phenotype, and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum Reprod. 2012; 27(10):1–12. doi: 10.1093/humrep/des232.
   PubMed Web of Science ®Google Scholar
• Steiner N, Ates S, Shaulov T, et al. Comparison of IVF outcomes transferring a single ideal blastocyst in women with polycystic ovary syndrome and normal ovulatory controls. Arch Gynecol Obstet. 2020;302(6):1479–1486. doi: 10.1007/s00404-020-05699-9.
   PubMed Web of Science ®Google Scholar
• Ashkenazi J, Farhi J, Orvieto R, et al. Polycystic ovary syndrome patients as oocyte donors: the effect of ovarian stimulation protocol on the implantation rate of the recipient. Fertil Steril. 1995;64(3):564–567. doi: 10.1016/s0015-0282(16)57793-0.
   PubMed Web of Science ®Google Scholar
• Liu L. Effect of kidney tonic and blood stasis formula on the expression of integrin α_Vβ_3 in patients with PCOS with kidney deficiency and blood stasis evidence. Hunan University of Traditional Chinese Medicine;2013. https://kns.cnki.net/KCMS/detail/detail.aspx?filename=1013183069.nh&dbcode=CDMD
   Google Scholar
• Zhao SX, Chen L, Zhan ZQ, et al. Progress in Chinese and Western medicine research on polycystic ovary syndrome-insulin resistance-reduced endothelial tolerance-early pregnancy loss. Jilin Chin Med. 2018;38(08):984–988. doi: 10.13463/j.cnki.jlzyy.2018.08.035.
   Google Scholar
• Ye Y, Zhou W, Ren Y, et al. The ameliorating effects of Guizhi Fuling Wan combined with rosiglitazone in a rat ovarian model of polycystic ovary syndrome by the PI3K/AKT/NF-κB and Nrf2/HO-1 pathways. Gynecol Endocrinol. 2023; 39(1):2254848. doi: 10.1080/09513590.2023.2254848.
   PubMed Web of Science ®Google Scholar
• Liu M, Zhu H, Zhu Y, et al. Guizhi Fuling Wan reduces autophagy of granulosa cell in rats with polycystic ovary syndrome via restoring the PI3K/AKT/mTOR signaling pathway. J Ethnopharmacol. 2021; 270:113821. doi: 10.1016/j.jep.2021.113821.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Li Y, Liu M, et al. Guizhi fuling wan, Chinese herbal medicine, ameliorates insulin sensitivity in PCOS model rats with insulin resistance by remodeling intestinal homeostasis. Front Endocrinol . 2020;11:575. doi: 10.3389/fendo.2020.00575.
   PubMed Web of Science ®Google Scholar
• Manzoor S, Ganie MA, Amin S, et al. Oral contraceptive use increases risk of inflammatory and coagulatory disorders in women with polycystic ovarian syndrome: an observational study. Sci Rep. 2019; 9(1):10182. doi: 10.1038/s41598-019-46644-4.
   PubMedGoogle Scholar
• Rossing MA, Daling JR, Weiss NS, et al. Ovarian tumors in a cohort of infertile women . N Engl J Med. 1994;331(12):771–776. doi: 10.1056/NEJM199409223311204.
   PubMed Web of Science ®Google Scholar
• Li L, Li G, Chen L, et al. Risk signal mining for letrozole based on the FDA adverse event reporting system database. J Adverse Drug React. 2020;22(9):511–517. doi: 10.3760/cma.j.cn114015-20190910-00752.
   Google Scholar
• Li S, Zhang B. Traditional Chinese medicine network pharmacology: theory, methodology and application. Chin J Nat Med. 2013;11(2):110–120. doi: 10.1016/S1875-5364(13)60037-0.PMID: 23787177.
   PubMed Web of Science ®Google Scholar
• Yan R, Yanjun D, En M, et al. Research progress and challenges of network pharmacology in field of traditional Chinese medicine. J Chin Herb Med. 2020;51(18):4789–4797. doi: 10.7501/j.issn.0253-2670.2020.18.024.
   Google Scholar
• Choudhary N, Choudhary S, Kumar A, et al. Deciphering the multi-scale mechanisms of Tephrosia purpurea against polycystic ovarian syndrome (PCOS) and its major psychiatric comorbidities: studies from network pharmacological perspective. Gene. 2021; 773:145385. doi: 10.1016/j.gene.2020.145385.
   PubMed Web of Science ®Google Scholar
• Xu X, Zhang W, Huang C, et al. A novel chemometric method for the prediction of human oral bioavailability. Int J Mol Sci. 2012;13(6):6964–6982. doi: 10.3390/ijms13066964.
   PubMed Web of Science ®Google Scholar
• Tao W, Xu X, Wang X, et al. Network pharmacology-based prediction of the active ingredients and potential targets of Chinese herbal radix Curcumae formula for application to cardiovascular disease. J Ethnopharmacol. 2013;145(1):1–10. doi: 10.1016/j.jep.2012.09.051.
   PubMed Web of Science ®Google Scholar
• Xiaojuan X, Lijuan Y, Zhang W, et al. Study on morphological changes of ovaries in a modified PCOS animal model simulating information on the characteristics of kidney deficiency phlegm and dampness. J Chengdu Univ Trad Chin Med. 2016;39(02):5–9 + 14. doi: 10.13593/j.cnki.51-1501/r.2016.02.005.
   Google Scholar
• Yang D, Wang T, Long M, et al. Quercetin: it is main pharmacological activity and potential application in clinical medicine. Oxid Med Cell Longev. 2020;2020:8825387–8825313. doi: 10.1155/2020/8825387.
   PubMed Web of Science ®Google Scholar
• Azeem M, Hanif M, Mahmood K, et al. An insight into anticancer, antioxidant, antimicrobial, antidiabetic and anti-inflammatory effects of quercetin: a review. Polym Bull. 2023;80(1):241–262. doi: 10.1007/s00289-022-04091-8.
   PubMed Web of Science ®Google Scholar
• Eisvand F, Tajbakhsh A, Seidel V, et al. Quercetin and its role in modulating endoplasmic reticulum stress: a review. Phytother Res. 2022;36(1):73–84. doi: 10.1002/ptr.7283.
   PubMed Web of Science ®Google Scholar
• Pourteymour Fard Tabrizi F, Hajizadeh-Sharafabad F, Vaezi M, et al. Quercetin and polycystic ovary syndrome, current evidence, and future directions: a systematic review. J Ovarian Res. 2020;13(1):11. doi: 10.1186/s13048-020-0616-z.
   PubMed Web of Science ®Google Scholar
• Wang Z, Zhai D, Zhang D, et al. Quercetin decreases insulin resistance in a polycystic ovary syndrome rat model by improving inflammatory microenvironment. Reprod Sci. 2017;24(5):682–690. doi: 10.1177/1933719116667218.
   PubMed Web of Science ®Google Scholar
• Imran M, Salehi B, Sharifi-Rad J, et al. Kaempferol: a key emphasis to its anticancer potential. Molecules. 2019;24(12):2277. doi: 10.3390/molecules24122277.
   PubMed Web of Science ®Google Scholar
• Devi KP, Malar DS, Nabavi SF, et al. Kaempferol and inflammation: from chemistry to medicine. Pharmacol Res. 2015;99:1–10. doi: 10.1016/j.phrs.2015.05.002.
   PubMed Web of Science ®Google Scholar
• Zhuang Z, Ye G, Huang B. Kaempferol alleviates the interleukin-1β-Induced inflammation in rat osteoarthritis chondrocytes via suppression of NF-κB. Med Sci Monit. 2017;23:3925–3931. doi: 10.12659/msm.902491.
   PubMed Web of Science ®Google Scholar
• Huang X, Pan Q, Mao Z, et al. Kaempferol inhibits interleukin‑1β stimulated matrix metalloproteinases by suppressing the MAPK‑associated ERK and P38 signaling pathways. Mol Med Rep. 2018;18(3):2697–2704. doi: 10.3892/mmr.2018.9280.
   PubMed Web of Science ®Google Scholar
• Yang JH, Shin BY, Han JY, et al. Isorhamnetin protects against oxidative stress by activating Nrf2 and inducing the expression of its target genes. Toxicol Appl Pharmacol. 2014;274(2):293–301. doi: 10.1016/j.taap.2013.10.026.
   PubMed Web of Science ®Google Scholar
• Ganbold M, Owada Y, Ozawa Y, et al. Isorhamnetin alleviates steatosis and fibrosis in mice with nonalcoholic steatohepatitis. Sci Rep. 2019;9(1):16210. doi: 10.1038/s41598-019-52736-y.
   PubMedGoogle Scholar
• Cai F, Zhang Y, Li J, et al. Isorhamnetin inhibited the proliferation and metastasis of androgen-independent prostate cancer cells by targeting the mitochondrion-dependent intrinsic apoptotic and PI3K/akt/mTOR pathway. Biosci Rep. 2020; 40(3):BSR20192826. doi: 10.1042/BSR20192826.
   PubMedGoogle Scholar
• Zhang F, Liu Z, He X, et al. β-sitosterol-loaded solid lipid nanoparticles ameliorate complete Freund's adjuvant-induced arthritis in rats: involvement of NF-кB and HO-1/nrf-2 pathway. Drug Deliv. 2020;27(1):1329–1341. doi: 10.1080/10717544.2020.1818883.
   PubMed Web of Science ®Google Scholar
• Babu S, Jayaraman S. An update on β-sitosterol: a potential herbal nutraceutical for diabetic management. Biomed Pharmacother. 2020; 131:110702. doi: 10.1016/j.biopha.2020.110702.
   PubMed Web of Science ®Google Scholar
• Ju YH, Clausen LM, Allred KF, et al. beta-sitosterol, beta-sitosterol glucoside, and a mixture of beta-sitosterol and beta-sitosterol glucoside modulate the growth of estrogen-responsive breast cancer cells in vitro and in ovariectomized athymic mice. J Nutr. 2004;134(5):1145–1151. doi: 10.1093/jn/134.5.1145.
   PubMed Web of Science ®Google Scholar
• Yu Y, Cao Y, Huang W, et al. β-sitosterol ameliorates endometrium receptivity in PCOS-Like mice: the mediation of gut microbiota. Front Nutr. 2021;8:667130. doi: 10.3389/fnut.2021.667130.
   PubMed Web of Science ®Google Scholar
• Evans J, Salamonsen LA, Winship A, et al. Fertile ground: human endometrial programming and lessons in health and disease. Nat Rev Endocrinol. 2016;12(11):654–667. doi: 10.1038/nrendo.2016.116.
   PubMed Web of Science ®Google Scholar
• Su J, Morgani SM, David CJ, et al. TGF-βorchestrates fibrogenic and developmental EMTs via the RAS effector RREB1. Nature. 2020;577(7791):566–571. doi: 10.1038/s41586-019-1897-5.
   PubMed Web of Science ®Google Scholar
• Park M-J, Lee D-E, Shim MK, et al. Piperlongumine inhibits TGF-β-induced epithelial-to-mesenchymal transition by modulating the expression of E-cadherin, Snail1, and Twist1. Eur J Pharmacol. 2017;812:243–249. doi: 10.1016/j.ejphar.2017.07.036.
   PubMed Web of Science ®Google Scholar
• Whitby S, Zhou W, Dimitriadis E. Alterations in epithelial cell polarity during endometrial receptivity: a systematic review. Front Endocrinol. 2020;11:596324. doi: 10.3389/fendo.2020.596324.
   PubMed Web of Science ®Google Scholar
• Thiery JP, Acloque H, Huang RY, et al. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139(5):871–890. doi: 10.1016/j.cell.2009.11.007.
   PubMed Web of Science ®Google Scholar
• Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest. 2009;119(6):1429–1437. doi: 10.1172/JCI36183.
   PubMed Web of Science ®Google Scholar
• Huber MA, Azoitei N, Baumann B, et al. NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest. 2004;114(4):569–581. doi: 10.1172/JCI21358.
   PubMed Web of Science ®Google Scholar
• Kumar M, Allison DF, Baranova NN, et al. NF-κB regulates mesenchymal transition for the induction of non-small cell lung cancer-initiating cells. PLOS One. 2013;8(7):e68597. doi: 10.1371/journal.pone.0068597.
   PubMed Web of Science ®Google Scholar
• Asgarova A, Asgarov K, Godet Y, et al. PD-L1 expression is regulated by both DNA methylation and NF-kB during EMT signaling in non-small cell lung carcinoma. Oncoimmunology. 2018; 17(5):e1423170. doi: 10.1080/2162402X.2017.1423170.
   PubMed Web of Science ®Google Scholar
• Hu M, Zhang Y, Li X, et al. Alterations of endometrial epithelial-mesenchymal transition and MAPK signaling components in women with PCOS are partially modulated by metformin in vitro. Mol Hum Reprod. 2020; 26(5):312–326. doi: 10.1093/molehr/gaaa023.
   PubMed Web of Science ®Google Scholar